Volastra Therapeutics

Volastra Therapeutics is seeking a Senior Clinical Data Manager to join our Clinical team. This newly created role will lead clinical data management activities for early-phase oncology trials and play a key role in ensuring high-quality data across our programs. This is an excellent opportunity for an experienced data management professional who enjoys working in a collaborative, fast-paced biotech environment and contributing to impactful oncology research. Learn more and apply: https://lnkd.in/e8XvVgtG #Hiring #ClinicalData #Medidata #Oncology #BiotechCareers #VolastraTherapeutics #NYCJobs

Volastra Therapeutics is seeking a motivated and experienced Clinical Project Manager / Senior Clinical Project Manager to support our oncology clinical development programs. This role will work across functions to manage the day-to-day operations of early-phase clinical trials, partnering closely with study teams, vendors, and leadership to drive execution, quality, and timely delivery of study milestones. This is an excellent opportunity for someone with strong clinical trial operations experience who thrives in a fast-paced biotech environment and is passionate about advancing novel cancer therapies. Learn more and apply: https://lnkd.in/eFUEQeCX

We’re pleased to announce the appointment of Timothy Bowler as Chief Medical Officer at Volastra. A board-certified medical oncologist, Tim most recently served as Volastra’s VP of Clinical Development, where he played a critical role in advancing our clinical programs and strengthening our development strategy. As CMO, Tim will lead Volastra’s clinical and medical efforts as we advance our oncology pipeline and programs targeting chromosomal instability. Learn more about Tim and read the full press release here: https://lnkd.in/dJ9DgA4S

Volastra is seeking a Scientist, Discovery Science to help advance our work in chromosomal instability (CIN) biology. In this role, you’ll drive critical experiments, develop and optimize assays, and generate insights that move programs from target validation through early pharmacology and into in vivo proof-of-concept. You’ll be part of a highly collaborative, multidisciplinary team and play a role in shaping our discovery pipeline in a fast-paced, innovation-driven environment.   If you’re excited to push the boundaries of CIN biology and contribute to building new cancer therapies, we’d love to hear from you.   Learn more and apply here: https://lnkd.in/eJmd9Z-d   #Hiring #DiscoveryScience #LifeSciences #BiotechCareers #Oncology #VolastraTherapeutics #NowHiring #NYCJobs

We’re looking for a Scientist/Senior Scientist, Preclinical Development & Translational Science to join our New York team and help advance our mission to bring new cancer therapies to patients by targeting chromosomal instability (CIN). In this role, you’ll drive translational and preclinical studies, collaborate across discovery and development teams, and play a key role in shaping programs from bench to clinic.   If you’re passionate about translational oncology and want to make an impact in a fast-moving, science-driven environment, we’d love to hear from you.   Learn more and apply here: https://lnkd.in/egSVw625   And check out our careers page for other open roles on our clinical team: https://lnkd.in/eB4punUt   #Hiring #PreclinicalDevelopment #TranslationScience #ClinicalTrials #LifeSciences #BiotechCareers #Oncology #VolastraTherapeutics #NowHiring #NYCJobs

Chromosomal instability (CIN) is present in 60–80% of all human cancers, with some tumors being almost universally unstable, including high-grade serous ovarian cancer. At Volastra, we’re developing new therapies for hard-to-treat cancers by leveraging #KIF18A inhibition to exploit CIN as a key vulnerability of these tumors. On Saturday at #ESMO2025, a special symposium will focus on chromosomal instability as a therapeutic vulnerability in cancer. Our co-founder and CSO, Dr. Samuel Bakhoum, will be among the speakers presenting his academic work. Also presenting will be Dr. Ecaterina Dumbrava of The University of Texas MD Anderson Cancer Center, one of the investigators leading our ongoing Phase I/II trial of VLS-1488, a novel, oral #KIF18A inhibitor. We’re excited to see the growing recognition of CIN as a powerful target in oncology and proud to be at the forefront of translating this biology into new medicines for patients.

We were proud to sponsor and participate in Together in TEAL on Long Island this past weekend, joining patients, families, and advocates in raising awareness and supporting those impacted by ovarian cancer. Organized by the National Ovarian Cancer Coalition, this event unites communities to fund critical research, education, and programming. Supporting events like Together in TEAL reflects our commitment to advancing new treatments for ovarian cancer and to partnering with the patient community every step of the way. Pictured: Volastra team members, joined by friends and family, at the Together in TEAL 2025 #NOCAM2025 #TogetherInTEAL #OvarianCancerAwareness #KnowOvarian

September marks National Ovarian Cancer Awareness Month—a time to unite and shine a light on ovarian cancer. Together, we can amplify voices, share stories, and spread awareness to help save lives and support those impacted by this disease. At Volastra, we are committed to advancing new treatments for patients with ovarian cancer through our two clinical-stage KIF18A inhibitors, with the goal of delivering meaningful impact for patients and their families. #NOCAM2025 #OvarianCancerAwareness #KnowOvarian

We’re pleased to share that our CEO, David Southwell, will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. We look forward to discussing our clinical-stage #KIF18A inhibitors and our mission to develop novel cancer therapeutics. #Oncology #Biotech #CIN

Last week, the Volastra team came together for a fun afternoon at the Empire Hotel in NYC. Enjoying the sunshine, food, and drinks allowed us to connect, recharge, and celebrate all of our hard work from the first half of 2025! #Biotech #NYC #Volastra